Dissociated effect of buserelin on luteinizing hormone (LH) and alpha subunit in men
- PMID: 1701778
- DOI: 10.1007/BF03348599
Dissociated effect of buserelin on luteinizing hormone (LH) and alpha subunit in men
Abstract
Chronic treatment with LHRH analogs is known to depress testosterone (T) values to castration levels. In contrast to results from animal experiments, studies in humans indicate that a pituitary-dependent mechanism predominates in the suppression of plasma T. However, this reduction in T levels may occur when LH values are within or below the normal range. One explanation for this result has been that while absolute values of LH in serum may not change, the bioactivity of LH is reduced. The present study has been performed to determine whether this discrepancy between LH and T values is obscured by the hypersecretion of the alpha-subunit which is devoid of any biological activity but crossreacts in most RIAs with LH. Following 2 days of blood collection to establish basal serum hormone levels, six men with prostatic cancer were treated with the LHRH agonist, Buserelin (500 micrograms sc, daily injection) for 15 days. The most significant endocrine responses at the end of this treatment were as follows: 1) T levels were depressed to the castration range; 2) no change was seen in the LH values with a conventional RIA procedure which crossreacted with the alpha-subunit; 3) a significant decrease was found in the LH values evaluated with an immunoradiometric (IRMA) method, which shows no cross-reactivity with the alpha-subunit; 4) there was a significant increase in the alpha-subunit levels; and 5) serum FSH levels were significantly decreased.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Prolonged treatment with the GnRH analogue buserelin does not affect alpha-subunit production by the pituitary gonadotroph.Clin Endocrinol (Oxf). 1990 Apr;32(4):443-51. doi: 10.1111/j.1365-2265.1990.tb00884.x. Clin Endocrinol (Oxf). 1990. PMID: 1693322
-
Concordant suppression of serum immunoreactive luteinizing hormone (LH), follicle-stimulating hormone, alpha subunit, bioactive LH, and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (detirelix).J Clin Endocrinol Metab. 1992 Feb;74(2):399-405. doi: 10.1210/jcem.74.2.1370507. J Clin Endocrinol Metab. 1992. PMID: 1370507 Clinical Trial.
-
The luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6-Pro9-NEt]LHRH increased rather than lowered LH and alpha-subunit levels in a patient with an LH-secreting pituitary tumor.J Clin Endocrinol Metab. 1984 Feb;58(2):313-9. doi: 10.1210/jcem-58-2-313. J Clin Endocrinol Metab. 1984. PMID: 6198331
-
Mechanisms of gonadotropin-releasing hormone agonist action in the human male.Endocr Rev. 1986 Feb;7(1):106-14. doi: 10.1210/edrv-7-1-106. Endocr Rev. 1986. PMID: 3007079 Review.
-
Gonadotroph cell adenomas of the pituitary.Endocr Rev. 1985 Fall;6(4):552-63. doi: 10.1210/edrv-6-4-552. Endocr Rev. 1985. PMID: 2416559 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources